Form 4: VolitionRx CEO Reynolds' RSU Vesting and Cancellations

VolitionRx CEO Cameron John Reynolds reported the vesting of 74,700 restricted stock units and the cancellation of 174,300 units, with vested shares subject to a three-year time-based schedule.

Summary

• Cameron John Reynolds, President and CEO, Director, and 10% Owner of VolitionRx Ltd, filed a Form 4 detailing changes in his beneficial ownership.
• On March 17, 2025, Reynolds was awarded 249,000 restricted stock units (RSUs) under the Issuer's 2024 Stock Incentive Plan.
• 74,700 RSUs vested due to the achievement of certain corporate performance goals by June 30, 2025, and December 31, 2025.
• These 74,700 vested RSUs are subject to a 3-year time-based vesting schedule, with 24,900 units vesting on March 17, 2026, 2027, and 2028, respectively.
• The remaining 174,300 RSUs did not vest and were cancelled on June 30, 2025, and January 22, 2026.
• Following the reported transaction, Reynolds directly owns 2,629,547 shares of common stock.
• Reynolds indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder, and 34,076 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a significant portion of RSUs (174,300) were cancelled, 74,700 RSUs did vest due to performance goal achievement, indicating some success in meeting corporate targets. This is a routine disclosure of executive compensation outcomes.

Positives

• 74,700 restricted stock units (RSUs) vested for the CEO due to the achievement of specific corporate performance goals, indicating some success in meeting company targets.
• The vesting aligns executive incentives with company performance, potentially benefiting shareholders if performance goals continue to be met.

Negatives

• 174,300 restricted stock units (RSUs) did not vest and were cancelled, indicating that a significant portion of the performance goals set for the award were not met.

Future Outlook

The filing indicates future time-based vesting of 74,700 RSUs in three equal installments on March 17, 2026, 2027, and 2028, which will result in the reporting person receiving common stock upon settlement.

Industry Context

This is an insider transaction report, which is a routine disclosure for executive compensation and ownership changes. It does not provide broader industry context or specific competitive insights.

Related Party Transactions

• The indirect ownership of 1,007,718 shares by Concord International, Inc., where Mr. Reynolds is the majority shareholder, and 34,076 shares by his spouse, are disclosed as existing beneficial ownership.

Stakeholder Impact

• Shareholders: The partial vesting of RSUs for the CEO aligns executive incentives with company performance, potentially benefiting shareholders if performance goals are met. The cancellation of a larger portion of RSUs indicates some targets were missed, which could be viewed neutrally or slightly negatively regarding internal performance.

Next Steps

• The reporting person will receive common stock upon the vesting and settlement of the 74,700 RSUs in three equal installments on March 17, 2026, 2027, and 2028.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting and cancellation of restricted stock units based on pre-defined performance and time-based criteria. It does not contain information that would fundamentally alter the investment thesis for VolitionRx Ltd. While some performance goals were met leading to partial vesting, a larger portion of RSUs were cancelled, suggesting mixed performance against internal targets. This information alone is insufficient to warrant a change from a 'hold' position, as it reflects standard compensation plan outcomes rather than new strategic or operational developments.

Keywords

VolitionRx, VNRX, Cameron John Reynolds, Form 4, Restricted Stock Units, RSU, Insider Trading, Beneficial Ownership, Stock Incentive Plan, Executive Compensation